compound introduction
Tofisopam has been used for studying its biochemical mechanisms of actions using drμg repositioning strategies1.
CAS number:22345-47-7 molecular formula:C22H26N2O4
Tofisopam has been used for studying its biochemical mechanisms of actions using drμg repositioning strategies1.
| Chinese alias | 托非索泮 | 1-(3,4-二甲氧基苯基)-5-乙基-7,8-二甲氧基-4-甲基-5H-苯并[d][1,2]二氮杂卓 | 1-(3,4-二甲氧基苯基)-5-乙基-7,8-二甲氧基-4-甲基-5H-2,3-苯并二氮杂卓 | ||
| English alias | Tofisopam (patented in japan) | (+/-)-1-(3,4-DIMETHOXYPHENYL)-5-ETHYL-7,8-DIMETHOXY-4-METHYL-5H-2,3-BENZODIAZEPINE | BCP09600 | 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine | 5H-2,3-Benzodiazepine, 1-(3,4-dimethox | ||
| CAS number | 22345-47-7 | molecular formula | C22H26N2O4 |
| molecular weight | 382.5 | Exact mass | ≥98% |
| PSA | 61.6 | logp | 3.2 |
| CAS | 22345-47-7 |
| UNII | UZC80HAU42 |
| HMDB ID | HMDB0015699 |
| KEGG ID | D01254 |
| ChEBI ID | 32241 |
| Wikidata | Q945537 |
| ChEMBL ID | CHEMBL404216 |
| Wikipedia | Tofisopam |
| DrugBank ID | DB08811 |
| DrugCentral | 2693 |
| PharmGKB ID | PA165958428 |
| PubChem CID | 5502 |
| Nikkaji Number | J11.504E |
| NCI 词表代码 | C90791 |
| Pharos Ligand ID | KZFLKDCNGXJS |
| DSSTox Substance ID | DTXSID3023681 |
| Metabolomics Workbench ID | 43726 |
| European Community (EC) Number | 244-922-3 |
| PubChem Reference Collection SID | 505894469 |
| International Nonproprietary Names (INN) | TOFISOPAM |
| XLogP3 | XLogP3-AA: 3.2 |
| 熔点 | 152 °C |
| 复杂性 | 579 |
| Exact Mass | 382.18925731 |
| 形式电荷 | 0 |
| 物理描述 | 固体 |
| 重原子计数 | 28 |
| Molecular Weight | 382.5 |
| Monoisotopic Mass | 382.18925731 |
| 可旋转键计数 | 6 |
| 氢键供体计数 | 0 |
| 氢键受体计数 | 6 |
| Kovats 保留指数 | 半标准非极性:3055.3 |
| 共价键单元计数 | 1 |
| 同位素原子计数 | 0 |
| 拓扑极性表面积 | 61.6 Ų |
| 定义键立体中心计数 | 0 |
| 定义原子立体中心计数 | 0 |
| 未定义键立体中心计数 | 0 |
| 未定义原子手性中心计数 | 1 |
No upstream information yet
No downstream information yet